Liposomal RNA Formulation Stability via Lipid Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods and compositions that enable the efficient delivery of biologically active RNA to target tissues with improved stability and shelf-life, particularly for parenteral administration, while maintaining RNA activity and compliance with GMP manufacturing standards.
Innovation Solution
The development of RNA lipoplex particles prepared using liposomes formed by injecting a concentrated lipid solution in ethanol into an aqueous phase, with specific lipid compositions and ratios, and methods for their production and storage that include freeze-drying or spray-drying to extend shelf-life without significant loss of RNA activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA is delivered using conventional lipoplex formulations, then RNA delivery to target tissues is achieved, but the formulations lack stability and shelf-life
Solution Approach 1:
The patent changes the physical and chemical parameters of the lipoplex formulation by adjusting lipid composition (ratio of cationic to helper lipid), pH value, and ionic strength. These parameter modifications enhance the structural stability of the lipoplex and prevent RNA degradation, thereby extending shelf-life while maintaining delivery efficacy.
Solution Approach 2:
The patent employs composite lipid formulations combining cationic lipids with specific helper lipids in defined ratios. This composite approach creates a synergistic effect where the helper lipids stabilize the cationic lipid structure and protect RNA, resulting in improved formulation stability and extended shelf-life.
2Duration of action of stationary object
If RNA lipoplex particles are stored for extended periods, then shelf-life is extended, but RNA activity is lost
Solution Approach 1:
The patent incorporates stabilizing agents and optimized lipid compositions that act as protective cushions before storage. These components prevent RNA degradation and maintain lipoplex structure during extended storage periods, ensuring RNA activity is preserved without substantial loss.
Solution Approach 2:
By optimizing pH, ionic strength, and lipid composition parameters, the patent creates a storage environment that maintains RNA stability. These parameter controls prevent RNA degradation and lipoplex disassembly during storage, preserving biological activity over extended periods.
3Manufacturing precision
If GMP-compliant manufacturing methods are implemented, then product quality is ensured, but manufacturing complexity increases
Solution Approach 1:
The patent divides the manufacturing process into distinct modular steps: lipid dissolution, liposome formation, RNA incorporation, and formulation adjustment. This segmentation allows each step to be optimized and controlled independently, ensuring GMP compliance while maintaining process manageability through standardized operations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in RNA lipoplex particles with enhanced biological activity and stability, allowing for effective delivery of RNA-encoded peptides or proteins to target tissues, maintaining activity over extended storage periods and meeting GMP compliance requirements.
Implementation Method 1
injecting a concentrated lipid solution in ethanol into an aqueous phase
Implementation Method 2
liposomes composed of a mixture of a cationic lipid and helper lipid to form injectable nanoparticle formulations
Implementation Method 3
RNA is bound to liposomes composed of a mixture of a cationic lipid and helper lipid
Implementation Method 4
delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration
Implementation Method 5
The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein
Data Source
AI summary
The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.